{"_id": "37658972|None", "id": "37658972", "infons": {}, "passages": [{"infons": {"journal": "AAPS PharmSciTech;2023Sep02; 24 (7) 179. doi:10.1208/s12249-023-02625-5", "year": "2023", "article-id_pmc": "2527668", "type": "title", "authors": "Singh S, Shukla R, "}, "offset": 0, "text": "Nanovesicular-Mediated Intranasal Drug Therapy for Neurodegenerative Disease.", "sentences": [], "annotations": [{"id": "1", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "Neurodegenerative Disease", "locations": [{"offset": 51, "length": 25}]}], "relations": []}, {"infons": {"type": "abstract"}, "offset": 78, "text": "Numerous neurodegenerative conditions, such as Alzheimer's, Huntington's, Parkinson's, amyotrophic lateral sclerosis, and glioblastoma multiform are now becoming significant concerns of global health. Formulation-related issues, physiological and anatomical barriers, post-administration obstacles, physical challenges, regulatory limitations, environmental hurdles, and health and safety issues have all hindered successful delivery and effective outcomes despite a variety of treatment options. In the current review, we covered the intranasal route, an alternative strategic route targeting brain for improved delivery across the BBB. The trans-nasal pathway is non-invasive, directing therapeutics directly towards brain, circumventing the barrier and reducing peripheral exposure. The delivery of nanosized vesicles loaded with drugs was also covered in the review. Nanovesicle systems are organised in concentric bilayered lipid membranes separated with aqueous layers. These carriers surmount the disadvantages posed by intranasal delivery of rapid mucociliary clearance and enzymatic degradation, and enhance retention of drug to reach the site of target. In conclusion, the review covers in-depth conclusions on numerous aspects of formulation of drug-loaded vesicular system delivery across BBB, current marketed nasal devices, significant jeopardies, potential therapeutic aids, and current advancements followed by future perspectives.", "sentences": [], "annotations": [{"id": "9", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "neurodegenerative conditions", "locations": [{"offset": 87, "length": 28}]}, {"id": "10", "infons": {"identifier": "MESH:D000544", "type": "Disease", "valid": true, "normalized": ["D000544"], "database": "ncbi_mesh", "normalized_id": "D000544", "biotype": "disease", "name": "Alzheimer Disease", "accession": "@DISEASE_Alzheimer_Disease"}, "text": "Alzheimer's", "locations": [{"offset": 125, "length": 11}]}, {"id": "11", "infons": {"identifier": "MESH:D006816", "type": "Disease", "valid": true, "normalized": ["D006816"], "database": "ncbi_mesh", "normalized_id": "D006816", "biotype": "disease", "name": "Huntington Disease", "accession": "@DISEASE_Huntington_Disease"}, "text": "Huntington's", "locations": [{"offset": 138, "length": 12}]}, {"id": "12", "infons": {"identifier": "MESH:D010300", "type": "Disease", "valid": true, "normalized": ["D010300"], "database": "ncbi_mesh", "normalized_id": "D010300", "biotype": "disease", "name": "Parkinson Disease", "accession": "@DISEASE_Parkinson_Disease"}, "text": "Parkinson's", "locations": [{"offset": 152, "length": 11}]}, {"id": "13", "infons": {"identifier": "MESH:D000690", "type": "Disease", "valid": true, "normalized": ["D000690"], "database": "ncbi_mesh", "normalized_id": "D000690", "biotype": "disease", "name": "Amyotrophic Lateral Sclerosis", "accession": "@DISEASE_Amyotrophic_Lateral_Sclerosis"}, "text": "amyotrophic lateral sclerosis", "locations": [{"offset": 165, "length": 29}]}, {"id": "14", "infons": {"identifier": "MESH:D005909", "type": "Disease", "valid": true, "normalized": ["D005909"], "database": "ncbi_mesh", "normalized_id": "D005909", "biotype": "disease", "name": "Glioblastoma", "accession": "@DISEASE_Glioblastoma"}, "text": "glioblastoma multiform", "locations": [{"offset": 200, "length": 22}]}, {"id": "15", "infons": {"identifier": "MESH:D008055", "type": "Chemical", "valid": true, "normalized": ["D008055"], "database": "ncbi_mesh", "normalized_id": "D008055", "biotype": "chemical", "name": "Lipids", "accession": "@CHEMICAL_Lipids"}, "text": "lipid", "locations": [{"offset": 1007, "length": 5}]}], "relations": []}], "relations": [], "pmid": 37658972, "pmcid": null, "meta": {}, "date": "2023-09-02T00:00:00Z", "journal": "AAPS PharmSciTech", "authors": ["Singh S", "Shukla R"], "relations_display": []}
